title: Effect of thyroid hormone on plasma apolipoproteins and apoA- and apoB-containing lipoprotein particles.
abstract: METHODS
  Apolipoprotein and apoB- and apoA-containing lipoprotein particle concentrations were determined in 10 athyreotic patients 4 weeks after withdrawal of Synthroid replacement therapy [T4, 0.96 +/- 0.66 microgram mL-1; thyroid-stimulating hormone (TSH), 62.7 +/- 22.8 muIU mL-1] and again 4 weeks after reinstitution of treatment.
  
  
  RESULTS
  Thyroid hormone replacement was associated with significant decreases in plasma cholesterol (TC), triglyceride (TG), apolipoprotein B and apolipoprotein C-III (P < 0.01). Both the cholesterol ester-rich LP-B particles and triglyceride-rich LP-Bc particles declined significantly in response to thyroid hormone (LP-B withdrawal 81.6 +/- 24.0 vs. replacement 65.1 +/- 22.0; LP-Bc withdrawal 14.3 +/- 6.0 vs. replacement 10.9 +/- 4.8 mg%, P < 0.01). ApoC-III also decreased in high-density lipoprotein (HDL) (apoC-III-HS), and in very low-density lipoprotein (VLDL) + low-density lipoprotein (LDL) (apoC-III-HP), but this reduction was proportionate so that the apo-C-III-HS/apoC-III-HP ratio, an indirect estimate of the efficiency of lipoprotein lipase (LPL), was unchanged. Apolipoprotein A-I concentrations also decreased significantly (withdrawal 140.7 +/- 27.0 vs. replacement 127.1 +/- 30.0 mg%, P < 0.01) in parallel with the changes in LP-A-I and LP-A-I:A-II particles (LP-A-I withdrawal 35.8 +/- 7.7 vs. replacement 31.5 +/- 6.3; LP-A-I:AII withdrawal 104.9 +/- 20.0 vs. replacement 95.5 +/- 26.0; P < 0.05).
  
  
  CONCLUSIONS
  These findings indicate that thyroid hormone influences the transport not only of both TG-rich and cholesterol-rich apoB-containing lipoprotein particles but also of those that contain apoAI.
authors.affiliation: Department of Medicine, Rush Medical College Chicago, IL, USA.
authors.forename: X Q
authors.initials: XQ
authors.lastname: Liu
authors.forename: A
authors.initials: A
authors.lastname: Rahman
authors.forename: J D
authors.initials: JD
authors.lastname: Bagdade
authors.forename: P
authors.initials: P
authors.lastname: Alaupovic
authors.forename: C R
authors.initials: CR
authors.lastname: Kannan
mesh_terms: D001054:Apolipoproteins A / Q000097:blood*; D001055:Apolipoproteins B / Q000097:blood*; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D015243:Cholesterol, VLDL / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013964:Thyroid Neoplasms / Q000601:surgery; D013965:Thyroidectomy; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood
chemical_list: D001054:Apolipoproteins A; D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D015243:Cholesterol, VLDL; D014280:Triglycerides; D013972:Thyrotropin; D002784:Cholesterol; D013974:Thyroxine